NEW CANCER TREATMENT USING NANOTECHNOLOGY INVENTED AT LET THERE BE HOPE TO BE USED IN CANCER STUDY TO GIVE HOPE TO PET DOGS WITH BONE CANCER
Augustus Pharmaceutical Development LLC, a startup pharmaceutical company, announced plans to develop an advanced nanotechnology treatment for bone cancer in pet dogs with untreatable osteosarcoma with support from the Let There Be Hope Medical Research Foundation.
Osteosarcoma is a common bone cancer in dogs as well as children and adolescents, often requiring long courses of chemotherapy, radiation, limb amputation, and frequently incurable.
This novel treatment uses a nanocarrier — one of the most promising advancements in biotechnology — into which a chemotherapy agent has been encapsulated, to target cells of the immune system that reside in the body’s lymph nodes. Targeted delivery of the chemotherapy agent to immune cells located in regional lymph nodes, into which tumors drain, has been shown to retard tumor growth and spread.
This unique nanocarrier was originally invented by scientists at Let There Be Hope Medical Research Institute, a California public nonprofit 501 c 3 foundation, to target HIV/AIDS virus residing intracellularly in lymph nodes where it evades treatment and survives in the human genome despite gold standard treatments. Scientists in Germany are now developing this technology with collaborators in Egypt and Brazil to eradicate the intracellular organisms that evade treatments for tuberculosis and hepatitis.
“Applying this same nanotechnology allows us to target immune cells whose normal functions to fight cancer are subverted by cancer’s relentless ability to survive”, Dr. Michael Scolaro said.
“While our initial study focuses on treating osteosarcoma, as a startup company, we have to think in small steps. Our future plans, however, are to apply this identical nanotechnology to cancers of the breast, prostate, colon and lungs. Let There Be Hope Medical Research Foundation, a nonprofit public charity, where the original nanotechnology was invented, is seeking public contributions to help give us a jump-start.”
Make a Tax Deductible donation here. Every dollar counts!
To advance medical research in cell-specific targeting of therapeutic agents for catastrophic medical diseases.
To offer innovative biotechnology solutions through cell-specific targeting of therapeutic agents that will implement clinical solutions and therapies for pandemic infectious diseases, autoimmune disorders, and cancers.
We support novel and promising Proof of Concept research into cell-specific targeted treatments of catastrophic diseases which have significant global impact. We believe there is an unfilled niche for funding creative and potentially important medical developments by scientists who are unable to obtain early grants from existing funding sources.
We will issue an annual request for proposals in three disease areas, to be announced by our Science Advisory Committee. Initially, we will review research proposals for targeted therapeutics in oncology, infectious diseases, and neurodegenerative disorders. Proposals will be independently reviewed and evaluated by the Science Advisory Committee. Grants for a maximum of $50,000 will be awarded in each of the designated disease areas, based on merit.